COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma

Michael Weichenthal, Dirk Debus, Lisa Zimmer, Imke von Wasielewski, Friedegund Meier, Thomas Tüting, Markus V. Heppt, Jessica C. Hassel, Fabian Ziller, Peter Mohr, Pia Dücker, Anca Sindrilaru, Edgar Dippel, Lucie Heinzerling, Marc Bender, Manar Aoun, Magdalena Walecki, Rudolf Herbst, Yenny Angela, Rudolf Stadler, Sebastian Haferkampf, Claus-Detlev Klemke, Kjell Matthias Kaune, Johannes Wohlrab, Ulrike Leiter, Nessr Abu Rached, Jochen Utikal, Gaston Schley, Jens Ulrich, Erwin Schultz, Christoffer Gebhardt, Patrick Terheyden, Ralf Gutzmer, Dirk Schadendorf

Open source

DOI: 10.3390/cancers18040667
Published: 2026-02-18
Container: Cancers
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers18040667,
  title = {COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma},
  author = {Michael Weichenthal and Dirk Debus and Lisa Zimmer and Imke von Wasielewski and Friedegund Meier and Thomas Tüting and Markus V. Heppt and Jessica C. Hassel and Fabian Ziller and Peter Mohr and Pia Dücker and Anca Sindrilaru and Edgar Dippel and Lucie Heinzerling and Marc Bender and Manar Aoun and Magdalena Walecki and Rudolf Herbst and Yenny Angela and Rudolf Stadler and Sebastian Haferkampf and Claus-Detlev Klemke and Kjell Matthias Kaune and Johannes Wohlrab and Ulrike Leiter and Nessr Abu Rached and Jochen Utikal and Gaston Schley and Jens Ulrich and Erwin Schultz and Christoffer Gebhardt and Patrick Terheyden and Ralf Gutzmer and Dirk Schadendorf},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18040667},
  url = {https://doi.org/10.3390/cancers18040667}
}

RIS

TY  - JOUR
TI  - COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
AU  - Michael Weichenthal
AU  - Dirk Debus
AU  - Lisa Zimmer
AU  - Imke von Wasielewski
AU  - Friedegund Meier
AU  - Thomas Tüting
AU  - Markus V. Heppt
AU  - Jessica C. Hassel
AU  - Fabian Ziller
AU  - Peter Mohr
AU  - Pia Dücker
AU  - Anca Sindrilaru
AU  - Edgar Dippel
AU  - Lucie Heinzerling
AU  - Marc Bender
AU  - Manar Aoun
AU  - Magdalena Walecki
AU  - Rudolf Herbst
AU  - Yenny Angela
AU  - Rudolf Stadler
AU  - Sebastian Haferkampf
AU  - Claus-Detlev Klemke
AU  - Kjell Matthias Kaune
AU  - Johannes Wohlrab
AU  - Ulrike Leiter
AU  - Nessr Abu Rached
AU  - Jochen Utikal
AU  - Gaston Schley
AU  - Jens Ulrich
AU  - Erwin Schultz
AU  - Christoffer Gebhardt
AU  - Patrick Terheyden
AU  - Ralf Gutzmer
AU  - Dirk Schadendorf
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18040667
UR  - https://doi.org/10.3390/cancers18040667
ER  -

APA

Weichenthal, M., Debus, D., Zimmer, L., Wasielewski, I. V., Meier, F., Tüting, T., Heppt, M. V., Hassel, J. C., Ziller, F., Mohr, P., Dücker, P., Sindrilaru, A., Dippel, E., Heinzerling, L., Bender, M., Aoun, M., Walecki, M., Herbst, R., Angela, Y., Stadler, R., Haferkampf, S., Klemke, C., Kaune, K. M., Wohlrab, J., Leiter, U., Rached, N. A., Utikal, J., Schley, G., Ulrich, J., Schultz, E., Gebhardt, C., Terheyden, P., Gutzmer, R., & Schadendorf, D. (2026). COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma. Cancers. https://doi.org/10.3390/cancers18040667

Source records

crossref · retrieved 2026-09-25T12:08:47.121Z